1

Next Generation Tools Enabling Personalized Medicine

Caliper Owners Group, May 17, 2011

2

Biologics & Vaccines:

Targeted Small Molecules

Stem CellsBiomarkers

Genome Sequencing:

Diagnostics Therapeutics

Imaging & Pathology

Disruptive Technologies Enabling Personalized Medicine More From Less, Faster and Better™

3

Triple Crown Focus

Innovation

CultureCollaboration

RevolutionizingMedicine

• Integration• Inspiration• Boldness

• Clinical Data• Technology• Business

• Patient Centric • Therapeutics• Diagnostics

4

Dennis Ausiello, MD

Chief of Medicine at Massachusetts General Hospital Chief Scientific Officer, Partners Healthcare System Jackson Professor of Clinical Medicine at Harvard Medical School Member of Board of Directors of Pfizer, Broad Institute and TARIS SAB member: Entra, Promedior, Pulmatrix, BIND Biosciences, Proventys Undergraduate degree from Harvard College and medical degree from

the University of Pennsylvania. Dr. Ausiello was elected to the Institute of Medicine of the National

Academy of Science in 1999 and the American Academy of Arts and Sciences in 2003.

He has made a substantial contribution to knowledge of epithelial biology in the areas of membrane protein trafficking, ion channel regulation and signal transduction. He has published numerous articles, book chapters, and textbooks and currently serves as the co-editor of Cecil's Textbook of Medicine, now in its 23rd edition.

“The Practice of Medicine in the 21st Century”

5

Next Generation Tools Enabling Personalized Medicine

Kevin HrusovskyPresident & CEO

Caliper Owners Group, May 17, 2011

6

State of Healthcare

Triple Crown Focus

Next Generation Tools Enabling Personalized Medicine

Innovation

CultureCollaboration

RevolutionizingMedicine

7

State of Healthcare

8

Lyman & Hirsch (2010), Personalized Medicine, pp223Life Expectancy is Slowing

50% decrease in infectious disease 30% decrease in infant mortality 40% decrease in smoking 30% decrease in premature cardiovascular deaths

Extending life has become more difficult Heart / Cancer account for 50% of deaths First time in two centuries, children‟s life

expectancy is shorter than parents – obesity Five year decline is projected

9

37% increase in obesity since 2000; 2/3 now overweight

Costs doubled to $150B since 2000 (10% of costs)

Costs projected to be $400B by 2020

Linked diseases: Diabetes, heart, kidney, cancer

Reverse correlation w/ per capita energy consumption

(NEJM, 2005; AHRQ, 2006; CBO, 2008; CDC, 2009)

Obesity Reduces Life Spans & Natural Resources

+

+=

10

Increasing for most every nation 15% of GDP and increasing

Quadrupled since 1980, but life spans have only increased by 3-4 years

Extending life significantly increases costs 65+ year olds spend 4x more per year

than under 65 5% consume 50% of medical care

Historical Increase in Healthcare Costs

Lyman & Hirsch (2010), Personalized Medicine, pp223

11

(83 failures)

Source: Arrowsmith. Nat. Rev. Drug Disc. v.10, p.1 (Feb 2011); Arrowsmith. Nat. Rev. Drug Disc. v.10, p.1 (May 2011)

High Failure Rate Pushes Up Cost of Health Care

INCREASED FAILURE RATE IN RECENT YEARS: PII failure rate increased to 82% and PIII to 50%

IMPROVE CLINICAL SUCCESS RATES THROUGH: Robust science and biomarker stratification earlier Clinically relevant tools and models

(108 failures)

12

Need for Personalized Medicine; $1 Trillion Wasted Annually

“If it were not for the great variability among individuals, medicine might well have been a science and not an art.”

Sir William Osler (1949-1919)

13

Cancer Needs Biomarkers and a Precision ApproachDrug Discovery Today, 2009

Top 15 Selling Oncology Drugs Generated $27B w/ 35% response

65% non response = $18B waste Toxicity + = $20B

Biomarkers Identify which patients benefit

Targeted therapies to „right” patients

HER2 test for HerceptinKRAS test for Erbitux

80% response rate

14

Drug Therapeutic Area Biomarker(s) Label Section

Atorvastatin Metabolic & Endocrinology LDL receptor Indications & Usage

Cetuximab Oncology EGFR, KRAS Indications & Usage

Dapsone Dermatology & Dental G6PD Indications & Usage

Dasatinib Oncology Philadelphia chromosome Indications & Usage

Imatinib Oncology C-Kit, FIP1L1-PDGFRa fusion, Philadelphiachromosome, PDGFR gene rearrangement

Indications & Usage

Lapatinib Oncology Her2/neu Indications & Usage

Maraviroc CCR5 CCR5 Indications & Usage

Nilotinib Oncology Philadelphia chromosome Indications & Usage

Panitumumab Oncology EGFR, KRAS Indications & Usage

Sodium Phenylacetate & Sodium Benzoate

Gastroenterology NAGS; CPS; ASS, OTC, ASL; ARG Indications & Usage

Sodium Phenylbutyrate Gastroenterology NAGS; CPS; ASS, OTC, ASL; ARG Indications & Usage

Tamoxifen Oncology ER Indications & Usage

Tositumomab Oncology CD20 antigen Indications & Usage

Trastuzumab Oncology Her2/neu Indications & Usage

Biomarkers and Companion DiagnosticsFDA REQUIRES CDx for 14 drugs (9 Oncology); RECOMMENDS CDx for 56 approved drugs

Source: FDA Table of Pharmacogenomic Biomarkers in Drug Labels (updated 1/13/2011)

$5B

$2B

$4B

15

Biomarkers – Enabling Discovery to Therapy in Record Time Reducing drug development costs by reducing size and time of clinical trials

Gerber & Minna (2010) Cancer Cell, v.18, pp. 548-551

3 years

16

Roche and Plexxikon are developing a companion diagnostic for PLX4032.“We are anticipating that we will be able to launch not only with the drug, but the diagnostic test at the same time.”

• Plexxikon / Roche: 81% metastatic melanoma patients with a BRAF (V600E ) activating mutation responded to treatment with PLX4032, a highly selective kinase inhibitor.

“These results represent a major breakthrough and provide proof that the treatment of metastatic melanoma can be individualized for a substantial percentage of patients.”

NEJM Editorial, August 26, 2010

“We have never seen an 80% response rate in melanoma, or in any other solid tumor, for that matter, so this is remarkable.”

Paul Chapman, M.D., Memorial Sloan-Kettering Cancer Center

Source: Flaherty et al., NEJM, v. 363, pp. 809-819

Melanoma – “BRAF Inhibitor and V600E Companion Diagnostic”

17

Genomics – From “Project” to Industry in One Decade Societal Impact of the Human Genome Project

According to American Medical Association…MEDICAL IMPACT – Current and Future “More powerful medicines” Better, safer drugs and vaccines the first time More accurate drug dosage

An unexpected benefit…Economic impactINVESTMENT: $6B spent by federal government) over 13 years

RETURN ON INVESTMENT (1988 to 2010): Economic impact of $800B, personal income of $250B, 3.8M job-years of employment ROI (for federal government and tax payers) = 141 In 2010, genomics-enabled industry generated $6B+ in taxes

Economic Impact of the Human Genome Project . Battelle Technology Partnership Practice (May 2011)

18

Life Expectancy Calculator

.

Country 100 yrs+ Per 100,000China 17,800 1.3Canada 3795 11.5UK 9330 15France 14,994 25Japan 36,376 28USA 95,548 31

"If you live to the age of a hundred you have it made because very few people die past the age of a hundred.”George Burns, 1896-1996

Ruth Frith, 100Shot-put gold medalist

Buster Martin, 101Marathoner, Life Enthusiast

Jaring Timmerman, 100World record for backstroke

Eemeli Vaynyrean, 100Inventor‟s gold medal

Centenarians and Super Centenarians

19

Cost of Extending Life Spans with Today‟s Medicine

Extending life from 77 to 84 years would double medical costs

$Bill

ions

Significantly ramp healthcare costs

65+ year olds spend 4x more per

person than under 65

5% of population consume 50% of

medical care

20

$400k Total Consumption Yields:- 77 year average lifespan- Additional year = $75k

~~

$2.5M

Colorectal Cancer:- Today: $250,000 adds 24 months- 1996: $500 adds 11 months

Extending Life Using Today‟s Tools is Prohibitive

21

Expand life from 77 to 100 years- Technology & Preventive Approaches

~~

$2.5M

A Revolution in Medicine is Needed to Extend Life Economically

22

Triple Crown Focus

Innovation

CultureCollaboration

RevolutionizingMedicine

• Patient Centric • Therapeutics• Diagnostics

23

2003R&D Start up• LabChip

2010Research Dx• LabChip• Imaging• Services

2011

Personalized Medicine• Biomarkers• Therapies• Diagnostics

+• Tissue• Imaging

+++- .5- .25

Caliper Strategic Transformation

Market $100M $1,000M $2,000MRevenue $20M $120M $142M Growth Declining 10% organic 15-22%G.M. 40% 52% 52%+EBITDA ($30M) $4M $4-6M

24

Biologics & Vaccines:

Targeted Small Molecules

Stem CellsBiomarkers

Genome Sequencing:

Diagnostics Therapeutics

Imaging & Pathology

Disruptive Technologies Enabling Personalized Medicine More From Less, Faster and Better™

25

In Vitro Tissue In Vivo

Preclinical

ClinicalResearch

Clinical

Existing Capability

Developing Capability

Future Capability

= $1B Market

26

+

Existing Capability

Developing Capability

Future Capability

Preclinical

ClinicalResearch

Clinical

In Vitro Tissue In Vivo

$1B Pathology

Market

= $2B Market

27

Automation

ImagingMicrofluidics

CRO Expertise / Experience

Revolutionary Technologies

Diagnostics Therapeutics

28

ImagingMicrofluidics• over 350 issued patents• prep and analytical LabChips• multiplexing and faster kinetics

CRO Expertise / Experience

Revolutionary Technologies

Diagnostics Therapeutics

Automation• high throughput, quality and low cost

29

Microfluidics – A Decade of Commercialization

Exponential Growth from 2000-2010 and Beyond

Transition from “Technology” to “Solution”

Positioned to Address Major uF Markets in Dx

Major Partnerships Underscore Market Potential

30

IsolateSample

FragmentSample

GenerateLibrary

Quant. Sample Sequence

Library Generation- Enzymatic reaction

- Purification

Extraction/PurificationDNA and/or RNA

Shear/FractionationSize select fragments

Quantification &Sample AnalysisPurity and integrity

SequencingSeq. chemistry

Zephyr GWNucleic Acid Extraction – Genomic Workstation

LabChip GXHT Bioanalyzer-like QC for DNA and RNA

Caliper Revolutionizing NGS Workflows – NGS Bundle

LabChip DS UV-Vis DNA/RNA Quantification

Sciclone NGS Walk Away Library Preparation

LabChip XTAutomated DNA Fractionation and Sizing

GW DS GX GXNGS XTXTFaster kinetic flow cells

• Enabling Throughput• Accuracy / Precision• Sample Preservation• Productivity / Quality

31

Challenge: Feed HiSeqs• 2-3 exomes/lane x 16 lanes/run = 48 exomes/run

• 1 Sciclone feeds 3-4 HiSeqs• Manual ≈ 24 samples per week per technician

• 1 Sciclone replaces 8 technicians

Benefits• Sequencer productivity; Lower cost; Increase throughput;

96 libraries 5 hours; 192 exome capture libraries per week

Methods• RNA preparation: Illumina TruSeq & NuGen• Library Prep: SOLiD, Illumina TruSeq, NEB, Nextera• Target enrichment: SureSelect & SeqCap EZ• Coming soon: Life PGM & Illumina MiSeq

Sciclone NGS

32

Molecular Diagnostics are Changing Medicine

($Billion) 2008 2011 2013 CAGRWW MDx Market1 $3.8 $6.0 $7.5 15%WW CDx Market2 $0.9 $1.6 $2.3 21%

1 Scientia Advisors, 2010.2 West LB Research; Caliper.

33

$10.5B Clinical Dx Automation Market by 2017

Pressure on clinical laboratories to increase cost-efficiency and productivity

Pressing need for robustness, efficiency and ease of use by non-experts

Abbott, Roche, Beckman, Bio-Rad, Qiagen, Siemens and Tecan

NGS Workstation (8x manual)Isolation and Library Preparation

LabChip GX (10x manual)QC: High Throughput Bioanalyzer

LabChip XT (12x manual)Fractionation and Sizing

Source: Global Industry Analysts, Inc., (GIA), April 2011

34

Caliper MDx Value Proposition

Ontario Agency for Health– Respiratory Virus Panel (RVP): > 25K tests / yr. ($1.25M)

– 2010 study: Qiagen, Luminex, Seegene (750 pts.)

Seegene / LabChip Dx RVP won Superior sensitivity, specificity, overall accuracy

30% reduction in lab tech labor vs. Luminex

Switching to Seegene RVP/LabChip Dx

35

Automation

Imaging Technology

• whole animal and tissue• LCTF/MSI capability• multiplex biomarker analysis

Microfluidics

Expertise and Experience

Revolutionary Technologies

Diagnostics Therapeutics

36

Imaging A Picture is Worth a Thousand Assays

Rapid, cost effective disease monitoring Predict drug efficacy with clinical applicability Earlier detection: single molecule imaging Accelerated pre-clinical discovery Identify biomarkers for companion Dx

0

20

40

60

80

100

120

140

0

200

400

600

800

1000

1200

1400

1600

Cu

mu

lative G

rant A

ward

s

IVIS Publications & NIH IVIS Funded Projects

Tota

l IV

ISP

ub

lica

tio

ns

0

10

20

30

40

50

60

70

80

2005 2006 2007 2008 2009 2010 2011E

TissueLicenseServiceProduct

Units Sold/YearInstalled Base

97278

120398

132530

Addressable Market: 8,000+ units in 2010

143673

154827

1761,003

190 est.1,193+

37

Revolutionary Molecular Imagers for Testing Molecules In Vivo

Rapid and cost effective approach to monitor disease progression

In depth understanding of disease in vivo

Observe functional biology real time in high throughput longitudinal experiments

Earlier detection: single cell imaging

Accelerate pre-clinical discovery

Translational and clinically practical

LuciferaseQuantum Fx- Low dose

uCT for structure co-registerwith optical for molecularFluorescent

probes

38

Novel COX-2 Probe for Cancer and Inflammation

Source: An Aspirin for Your Cancer? The Scientist (April 2011)

Cyclooxygenase-2 probe

The COX-2/PGE2 pathway plays an important role in

many types of cancer

COX-2 is highly expressed in almost every type of

tumor at the early stages of tumor formation.

COX-2 is a useful biomarker in many tumor types

39

Targeting Tumor COX-2 Expression with FluoroCoxib A Probe

FluoroCoxib A 5-ROX (control dye)

HT29-luc2COX2 (+)

HCT116-luc2COX2 (-)

FluoroCoxib A : In vivo biomarker probe with clinical translatability

40

“Technologies that Stimulate the Inquisitive Mind”

PMCC‟s vision: “The best in cancer care, accelerating discovery, translating to cures”

Also owns a Caliper “automated gene knockdown machine” in their functional genomics lab

“Elliot‟s Machine” – Peter MacCallum Cancer Center

41

Caliper Imaging Platform Overview

Lumina II: Entry level bioluminescent/

fluorescent imaging

Lumina XR: Lumina with x-ray overlay

Spectrum: Quantitative 2D

and 3D optical imaging

Kinetic: Fast, Real-time molecular imaging

Maestro 2: Fully Automated premium

fluorescence Imaging System

Maestro EX: Entry-Level

Fluorescence In Vivo Imaging

System

Quantum FX:Fast, low dose uCT

42

In Vivo Validation: Non-specific (palpation, IHC) vs. Specific (molecular, FISH)

Can only tell that a particular antigen is present. Not that the antibody was bound to that antigen

Shows location of fluorophore inside tumor.

This is critical for validation in vivo results

43

Traditional Pathology becoming “Prone To Error”

* New York Times, Prone to Error: Earliest Steps to Find Cancer, July 19th, 2010

Traditional tissue pathology in breast cancer

• 90,000 Ductal Carcinoma in situ (D.C.I.S.) cases are misdiagnosed

Multiple biomarker classification for breast cancer prognosis / treatment

• Her2 IHC status alone has 22% false positives and 9% false negatives• Estrogen Receptor / Progesterone receptor status alone – 10-20% false positive

Quantitative, structural, multiplex biomarker data can improve diagnosis

Traditional H&E

44

Signaling Node Analysis in FFPE Tissue from Lung Cancer

Conventional Color Image

Spectral signal isolation

Pattern-recognition image analysis

Multiplexed pAKT, pERK, & pS6 (plus DAPI) – Integrated Reagent Kit Capability (CST, HistoRx)

Signal Composite Image

Analyzed Image

VectraTM Per-cell multi-parameter data

Autofluorescence removed

45

Isolating Fluorescence Signals with Spectra

Nuance uses LCTF technology to acquire images at many wavelengths to better determine fluorophore/stain distribution in cells or tissue

Monochrome Color (RGB) Multispectral

420nm

490nm

720nm

46

Eliminates autofluorescence from other labels

Signal in conventional approach was 2/3 autofluorescence

‘Unmixed’ EGFR signal

Monochrome bandpass image

23.4

1.3

0.4

69.1

99.9

6.9

Signal (Cts)

membrane 23.4

nuclear 1.3

Off sample 0.4

Signal (Cts)

membrane 69.1

nuclear 99.9

Off sample 6.9Conventional

Detecting EGFR in breast tissue

Multispectral

Signal Isolation Gives Improved Accuracy and SensitivityIF signal advantages apply to FISH too

S/B: 0.7 to 1

S/B: 18 to 1

47

Enhancement of FISH Dots with Spectral Components

conventional RGB spectral composite

48

Leading Pathologists Using Caliper MSI for Multiplexed Analysis of Tissue

Principle Invest. Institution Multiplexing Enablement

Massimo Loda Dana Farber Prostate cancer stratification (PI3K pathway – pAKT, pERK, pS6, stathmin)

Kent Osborne Baylor Breast cancer stratification (multiplexed Her1/2/3)

David Rimm Yale (HistoRX founder) Breast cancer aspirate prognostic, trainable pattern recognition

Gustavo Ayala Baylor Prostate cancer, prognostic based on tumor microenvironment analysis

Jennifer Hunt Mass General Hosp. Head & neck, multiplexed FISH prognostic (HPV 16, 18, and 33)

Humphrey Gardner Novartis Breast and lung cancer, Ph1 trials (PI3K pathway –pAKT, pERK, pS6)

Andrea Richardson Harvard Med. School Breast cancer stratification (multiplexed mRNA in FFPE)

Roger McLendon Duke University Brain cancer, multiplexed IHC prognostic

Carlo Croce Ohio State Univ. Multiplexed miRNA analysis in cancer FFPE

Mike Feldman Univ. of Penn Med. School Many cancers, multiplexed analysis for tumor infiltrating lymphocyte count, transplant rejection, proliferation assessment, etc.

Ken Bloom Clarient Breast Cancer, Multiplexed FISH and CISH

49

Cancer: Uncontrolled Cell Growth

Personalized medicine

1. What is the Biology ?

2. How can we affect and modulate the biology?

3. How can we predict and affect individual specific biology?

50

Caliper‟s unique Multiplexing

assay capability

Research biomarker

Approved diagnostic

51

Need for Multiplexed TechnologiesGetting “more from less” is critical for clinical decision-making

Horn & Pao (2009) JCO, v.26, pp. 4232-4234; Bunn & Doebele (2011) JCO, v.29, pp.1-3

Optimal treatment

Simultaneous Molecular Testing

Serial Molecular Testing (Reflex approach)*Multiplexing

52

Tissue Imaging Technology – Potential impact on MDx / CDx

• Reduction of false positives and negatives

• Multiplexing provides more accurate testing from less sample, faster

• Multi spectral imaging technology enables cleaner resolution and higher multiplexing

• Pattern recognition enables automated analysis and quantification

• Alternative representation, i.e., pseudo H&E, combined FISH / IF, Quantitative ISH or IF

ALK-FISH negative specimen

ALK-FISH positive specimen

53

Why CTC Analysis is a Game-changer

Cancer detection todaySymptom based – detection often after metastasis

Typically on primary tumor, metastatic cells are different

The promise of CTC-based analysisLiquid biopsy – non-invasive and routine

Detect metastasis before symptoms

Prognostic (> 5 CTCs per 7.5 mL of blood = aggressive)

Predictive and response / resistance monitoring

$1B investment today

Research, clinical trials and companion diagnostics

54

Circulating Tumor Cells; “one / 10 million” to “one / billion”

Yu M et al. JCB 2011;192:373-382

LabChipGX/DX

Labchip XT

Nuance/ Vectra

55

Disruptive Technologies for Important Applications

Minimizes sample yield loss

Reduces PCR biases

High quality results from smaller samples

Sciclone® G3 / Zephyr® Workstation

LabChip® GX – XT – DS – Dx

Critical IP for NGS platforms

Products More from Less, Faster and Better

Distinguishes heterogeneity / morphology intact

Accelerated small animal trials

IVIS® Lumina II

IVIS® Kinetic / Spectrum

Rapid enzyme screening and profiling for small molecule discovery programs

CRO stratification studies for tox / efficacy; Enabling drug rescue platform

LabChip® GX I / EZR – DNA, RNA, Epigenetics, Kinase, Protease, etc.

Drug Rescue – Tox - Oncology

Genome Sequencing

Imaging & Pathology

Biomarkers / MDx

Biologics & Vaccines

Targeted Small Mol

Stem Cells

Dia

gnos

tics

Ther

apeu

tics

LCTF enables multispectral / multiplexing

Eliminates auto florescence

Biomarker to CDx regulatory scale up

Nuance / Vectra / CTCs

Digital pathology platforms

LabChip® Dx + Automation

Gold standard BM discovery / validation tools LabChip® GX II – Proteins - Biologics

Many quantitative tests simultaneously IVIS® Kinetic

Emerging investment area

56

Imaging TechnologyMicrofluidic Technology

CRO expertise / experience

• pharma / bio experience• Tox / efficacy / data base• MDx / CDx / Rescue

Revolutionary Technologies

Diagnostics Therapeutics

Automation and Robotics

57

Biomarker Selection

- Annotated Panel of 200+ human cancer lines (wide range; breast, GI)

- biomarkers identification (FISH,IHC…)

Pharmacology & Genetics

- Drug susceptibility/resistance & genetic/biomarkers information

- Optimum monotherapy & drug combination treatments

- In vivo efficacy, PK/PD, dosing

Patient Stratification

- Biomarker identification of disease progression, drug susceptibility and resistance for better trials

- Align Rx and CDx development

- Competitive market differentiation

Oncology Biomarkers: In vitro to In vivo to Human Program

58

Triple Crown Focus

Innovation

CultureCollaboration

RevolutionizingMedicine

• Clinical Data• Technology• Business

59

Revolutionary Themes Drive Product Line Investments

Genome Sequencing

Imaging & Pathology

Biomarkers

Biologics & Vaccines

Targeted Small Mol

Stem Cells

Dia

gnos

tics

Ther

apeu

tics

• Emerging R&D investment opportunity

60

Improving Clinical Relevance with Rapid Innovations Cycles

Bringing technology, discovery, and development closer to patients

IRB re-invention

61

Triple Crown Focus

Innovation

CultureCollaboration

RevolutionizingMedicine

• Integration• Inspiration• Boldness

62

Secretariat Movie Clip

Sham = Cancer

63

First triple crown winner in 25 years

World record at Kentucky Derby

World record at Preakness

World record at Belmont Stakes

Only non human Man of the Year

Heart 2.5x the size of most race horses

One Vision, One Team – Triple Crown

64

What excites you about working with our customers, focusing on patients and

winning the Triple Crown?

Next Generation Tools

TODAY TOMORROW

Exploring Solving Building

65

Common Greater Purpose

Improve the quality and length of life for all mankind by commercializing disruptive technologies that enable a revolution in personalized health care.

66

Mark Roskey

67

Joe Griffith

68

Will Kruka

69

Paula Cassidy

70

Nate Cosper

71

Abbie Esterman

72

Abdel Bensaid

73

Anna Christensen

35 feet in the air, showing a group of eager sailors how to climb a mast……

74

Arthur Weissman (Mad Scientist)

“If only I had CDAS test this in Toxcast before I drank it!”

75

Bob Gardner

76

Chris Maki

77

Christian Lehmann

78

Cliff Hoytt

79

Darren Lee

Saving 1 Life

80

Hao Chen

81

Josh Molho

82

Mike Marlowe

83

Olga Campa

84

Peter Kuemmel

85

Philippe Mourere

86

Rick Ekstrom

87

Stephane Mouradian

88

Tommy Takanose

89

Wayne Lee

90

91

92

Stakeholder Input

Kathryn Tunstall Caliper BOD

Bob Burt Pfizer BOD

Ross Muken Deutsche Bank

93

Patient as Partner: John & JP Hussman• Ph.D. in Economics from Stanford

• Manages $8B hedge fund; Beat S&P 500 past decade

• JP, his17 year old son is autistic

• Hussman funded U Miami Institute of Human Genetics

• Spends all his free time studying genetics

• Used quantitative investment algorithms to analyze genes

• Published a paper linking genes to autism

Hussman's map of autism-related proteins

94

Caliper Stock up 400% in past two years

CALP

S&P 500

95

Open our Minds and Learn from OthersSteal Shamelessly Best Practices• Secretariat• Invictus• Coach Carter• Remember the Titans• Apollo 13• Rudy

Long Life Resources• http://www.livingto100.com/• http://www.realage.com• http://www.healthstatus.com/• http://www.personalgenomes.org/• http://www.webmd.com/• http://familyhealth.com/

Innovation Reading List & Resources

96

Willard ScottRick‟s Mom, Eva Bernal 104 years!Passed in January 2009

In Loving Memory

My Mom, Eileen Hrusovsky 81 years! BUCKEYE Grandma

Passed in July‟07In Loving Memory

Randy Pausch

97

Thank You!Acknowledgements:

Caliper Customers and Collaborators

Caliper Team:Irene Rombel, Ph.D., Mark Roskey, Ph.D., Nate Cosper, Ph.D., Isaac Meek, Seth Cohen, Ph.D., Anna Christensen, Ph.D., Darren Lee, Cliff Hoyt, Dan Rippy, Jeremy Lambert, Philippe Mourere, Rick Bunch, Andrew Barry, Kevin Francis, Ph.D., Denise DiRenzo, Gloria Martel, Julie McNiff, Ross Nakatsuji, Julie Coughlan, Diane Kosheff and Cathy Portanova

98

Secretariat Movie Clip

Sham = Cancer

99

One Vision One Team – Triple Crown

We have an unprecedented opportunity to impact patients

We are responsible for our mindset, belief system and unconquerable spirit

We must be masters of our fate to unleash this “Tremendous Machine”

What are the ingredients for Greatness?

- Inspire yourself and the great team around you

- Work together to build and use this tremendous machine to benefit patients

- Never Ever give in to anything but progress. Will our way forward.

- Make this our personal destiny, make this our personal moment

We can do it! We will do it! Our future starts right now and is in your capable hands…

100

Stephan Schuster, PhD

Professor of Biochemistry and Molecular Biology, Pennsylvania State University Studied chemistry at the University Munich and Konstanz (Germany) and

biochemistry at the Max-Planck-Institute for Biochemistry in Germany Postdoctoral studies at the California Institute of Technology, Pasadena, USA

His research group currently studies use of high-throughput sequencing in several areas of biology, including metagenomics, evolutionary biology and ancient

Co-Leader, Southern African Genome Project Project Leader, Wooly Mammoth Genome Project

“African Genomics: Charting Human Diversity”